Enlivex Doses First U.S. Patient in Phase 2b Trial for Knee Osteoarthritis Drug Allocetra™
ENLV is trading near its 52-week low of $0.66 (6.3% above the low).
Summary
Enlivex announced the dosing of the first U.S. patient in its Phase 2b clinical trial for Allocetra™ to treat moderate-to-severe knee osteoarthritis, following recent regulatory approvals.
Key Events · Product Development and Regulatory · ENLV
-
Phase 2b Trial Advancement
Enlivex has dosed the first patient in the United States for its global Phase 2b clinical trial of Allocetra™ for moderate-to-severe knee osteoarthritis.
-
Regulatory Milestones Achieved
This milestone follows FDA Investigational New Drug (IND) clearance in March 2026 and Danish Medicines Agency (DKMA) approval in April 2026, enabling global enrollment.
-
Addressing Unmet Need
The trial targets a highly prevalent and disabling disease with no approved disease-modifying therapies, representing a significant market opportunity.
Analysis · ENLV · Life Sciences
This marks a critical advancement for Enlivex's lead therapeutic candidate, Allocetra™, as it begins enrolling patients in the United States for its Phase 2b trial. Dosing the first patient in a major market like the U.S. demonstrates significant progress in the clinical development pathway for a drug targeting a prevalent disease with high unmet medical need.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENLV was trading at $0.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $171.1M. The 52-week trading range was $0.66 to $2.10. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.